Yesterday morning Dexcom CEO Kevin Sayer rang the opening bell for the Nasdaq later that afternoon Insulet CEO Jim Hollingshead rang the closing bell. Noticeably absent from the podium was Tandem CEO John Sheridan. While Mr. Sayer and Mr. Hollingshead are being cheered by their stakeholders Mr. Sheridan is lucky, he’s not being whacked by Tandem stakeholders.
Since taking over as CEO on March 1, 2019, Tandem shares have fallen over 74%, by comparison Dexcom shares have risen almost 188% Insulet up over 85%. According to Salary.com over the last three years Mr. Sheridan has earned almost . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.